Blocking the interaction between CD40/CD40L, using genetic or pharmacological (i.e., monoclonal antibody) means, has been implicated in various autoimmune diseases such as rheumatoid arthritis (Karnell et al., 2019). This evidence concerns the gene CD40 and autoimmune disease.